Brian Shaffer

BMT Physician @MSKCC | @WeillCornell Graduate School | NK Cell Immunotherapy | Passionate about nature and family

[Brian Shaffer @BrianShafferMD]

One of my favorite things to write with two colleagues from whom I’ve learned a great deal. @MSKCancerCenter

https://t.co/yaeAioiGaJ

[NMDP @nmdp_org]

🚨 BIG NEWS in Cell Therapy! 🚨

New donor selection guidelines—developed with @CIBMTR & partners—are now published in the Journal for Transplantation and Cellular Therapy! 🧬

They reflect the latest in GVHD, expanded donor options & search strategies.
🔗 https://t.co/xNqO8HOrG0

[MSK Library @MSKLibrary]

Featured today by @MSKLibrary: Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703 https://t.co/veSIVIbptr

#BMTCTN1703 #PatientReportedOutcomes #QualityOfLife #TransplantResearch
@sghmd @GvHD_Meade @DrMonzrAlMalki #JuanWu #CarrieLKitko #RanReshef @AndrewRezvan @BrianShafferMD @MelhemSolh @YaoJanny @LRunaas #HanyElmariah #KarilynTLarkin #NajlaElJurdi @MGooptu #AlisonLoren @AricHallMD #AminMAlousi #OmerJamy #WilliamClark @KeanMD @AmiBhattMD #MiguelAngelPerales #KristyApplegate
@YEfebera #EricLeifer #RichardJJones @bmtdata #DeborahMattila @wlsaber @MediHumdani #MichaelJMartens

[MSK Department of Medicine @MSK_DeptOfMed]

Just out in @ASTCT: Updated allogeneic stem cell donor selection guidelines from the CIBMTR/NMDP. Kudos to @mskcancercenter's @BrianShafferMD and team! #stemcelltransplant #Cancer https://t.co/0w7mpLwQiZ

[Brian Shaffer @BrianShafferMD]

Updated allogeneic stem cell donor guidelines from the CIBMTR/NMDP. A collaborative effort with many wonderful colleagues. Guidelines are adapted for donor selection when using PTCY.

https://t.co/UqXxine4Sl

[Steven Devine @DrStevenDevine]

Proud to share @JCO_ASCO paper of the ACCESS study run by @CIBMTR and sponsored by @nmdp_org 145 recipients of MMUD grafts using PTCy experienced outcomes similar to matched transplants, including <7/8 grafts. 59% of patients were diverse!

[CIBMTR @CIBMTR]

NEW study results just published in @JCO_ASCO: Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis Following Mismatched Unrelated Donor PBSC Transplantation. Read more: https://t.co/i1Vk9zQoAk

[Mahasweta Gooptu @MGooptu]

Amazing to have been part of this endeavour! #donorsforeveryone
@DrStevenDevine @BrianShafferMD @amjimenezmd @DrMonzrAlMalki @JeffAuletta @spellman_s

[Brian Shaffer @BrianShafferMD]

San Diego Day 2 for #ASH24 — This is the version you get if you’re from the east coast and you wake up at 3:30 AM.

[Antonio Jimenez Jimenez @amjimenezmd]

Excited to share our latest perspective on AML MRD in @BMTjournal. Grateful for the opportunity to team up again with @BrianShafferMD, @DrMarcosdelima, and P. Kebriaei. Looking forward to ongoing work with #MRDguru 🙌@DrChrisHourigan!

https://t.co/5lDq3TdbLd

[Shernan Holtan MD @sghmd]

Here we go! @BrianShafferMD leading us through the morning session addressing controversies re: #PTCy. Dose? Alternatives? Toxicities? @ASTCT #ToxicitiesConference24

[Brian Shaffer @BrianShafferMD]

For heme/onc fellows that are interested in specialized training in cellular therapy, @MSKCancerCenter offers an advanced fellowship in BMT/Cellular Therapy!

DM me with specific questions, details 👇👇👇I’ll be at #ASH24 if you want to meet.

https://t.co/wL2dNoC3fs

[Brian Shaffer @BrianShafferMD]

https://t.co/pEG4gw1Ms5

[CIBMTR @CIBMTR]

New CIBMTR Research – the first analysis from @BMTCTN 1702! Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional Trial. Read more, here:
https://t.co/9c1QatT47W

[Brian Shaffer @BrianShafferMD]

The AI model was trained at the Mayo Clinic and validated on BMT patients treated at MSKCC.

[Brian Shaffer @BrianShafferMD]

Very pleased to share our collaborative work with @MayoClinic @MSKCancerCenter. We used AI to evaluate pre transplant ECG images to predict arrhythmia after #BMT. AI-ECG predicted death after allogeneic HCT.

https://t.co/uQFfG2sNWA

[Brian Shaffer @BrianShafferMD]

We believe the use of computer vision on ECGs to predict cancer treatment toxicity is a new paradigm in personalized cancer care, and that this approach may be applicable to other cancer treatments that may be cardiotoxic. More to come!

[Journal of Clinical Oncology @JCO_ASCO]

Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors ➡️ https://t.co/z6TgWikO34 @BrianShafferMD @DrStevenDevine #hemonc

[Brian Shaffer @BrianShafferMD]

@ReshmaRamlal2 @sghmd @CIBMTR @nmdp_org @MGooptu @GvHD_Meade @spellman_s @amjimenezmd @DrMonzrAlMalki There are conflicting smaller studies. Severe chronic GVHD is infrequent after full dose PTCy, making it hard to look. You could use the public @CIBMTR datasets to explore this further. Great question!